{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:50:32Z","timestamp":1787550632962,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T00:00:00Z","timestamp":1495843200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10067-017-3689-3","type":"journal-article","created":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T07:09:47Z","timestamp":1495868987000},"page":"2169-2178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases"],"prefix":"10.1007","volume":"37","author":[{"given":"Mai","family":"Kawazoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaichi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Shikano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Kusunoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Nanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,27]]},"reference":[{"key":"3689_CR1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Van Staa","year":"2000","unstructured":"Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993\u20131000. doi: 10.1359\/jbmr.2000.15.6.993","journal-title":"J Bone Miner Res"},{"key":"3689_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMcp1012926","volume":"365","author":"RS Weinstein","year":"2011","unstructured":"Weinstein RS (2011) Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 365:62\u201370. doi: 10.1056\/NEJMcp1012926","journal-title":"N Engl J Med"},{"key":"3689_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00774-004-0596-x","volume":"23","author":"H Nawata","year":"2005","unstructured":"Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23:105\u2013109. doi: 10.1007\/s00774-004-0596-x","journal-title":"J Bone Miner Metab"},{"key":"3689_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP Van Staa","year":"2002","unstructured":"Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777\u2013787. doi: 10.1007\/s001980200108","journal-title":"Osteoporos Int"},{"key":"3689_CR5","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319\u20131328. doi: 10.1007\/s00198-007-0394-0","journal-title":"Osteoporos Int"},{"key":"3689_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S2213-8587(13)70045-7","volume":"1","author":"MJ Seibel","year":"2013","unstructured":"Seibel MJ, Cooper MS, Zhou H (2013) Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol 1:59\u201370. doi: 10.1016\/S2213-8587(13)70045-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3689_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11914-014-0197-0","volume":"12","author":"N Gua\u00f1abens","year":"2014","unstructured":"Gua\u00f1abens N, Gifre L, Peris P (2014) The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis. Curr Osteoporos Rep 12:90\u201397. doi: 10.1007\/s11914-014-0197-0","journal-title":"Curr Osteoporos Rep"},{"key":"3689_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrendo.2013.154","volume":"9","author":"E Canalis","year":"2013","unstructured":"Canalis E (2013) Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol 9:575\u2013583. doi: 10.1038\/nrendo.2013.154","journal-title":"Nat Rev Endocrinol"},{"key":"3689_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.3074","volume":"19","author":"R Baron","year":"2013","unstructured":"Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19:179\u2013192. doi: 10.1038\/nm.3074","journal-title":"Nat Med"},{"key":"3689_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2011.10.044","volume":"492","author":"DG Monroe","year":"2012","unstructured":"Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ (2012) Update on Wnt signaling in bone cell biology and bone disease. Gene 492:1\u201318. doi: 10.1016\/j.gene.2011.10.044","journal-title":"Gene"},{"key":"3689_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","volume":"93","author":"M Rossini","year":"2013","unstructured":"Rossini M, Gatti D, Adami S (2013) Involvement of WNT\/\u03b2-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93:121\u2013132. doi: 10.1007\/s00223-013-9749-z","journal-title":"Calcif Tissue Int"},{"key":"3689_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1210\/er.2011-1060","volume":"33","author":"HZ Ke","year":"2012","unstructured":"Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33:747\u2013783. doi: 10.1210\/er.2011-1060","journal-title":"Endocr Rev"},{"key":"3689_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00223-010-9372-1","volume":"87","author":"MJ Moester","year":"2010","unstructured":"Moester MJ, Papapoulos SE, L\u00f6wik CW, van Bezooijen RL (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87:99\u2013107. doi: 10.1007\/s00223-010-9372-1","journal-title":"Calcif Tissue Int"},{"key":"3689_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","volume":"32","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, Ozono K, Sagawa A, Takayanagi R, Tanaka H, Miki T, Masunari N, Tanaka Y (2014) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 32:337\u2013350. doi: 10.1007\/s00774-014-0586-6","journal-title":"J Bone Miner Metab"},{"key":"3689_CR15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/ard.42.6.655","volume":"42","author":"JV Bertouch","year":"1983","unstructured":"Bertouch JV, Roberts-Thompson PJ, Feng PH, Bradley J (1983) C-reactive protein and serological indices of disease activity in systemic lupus erythematosus. Ann Rheum Dis 42:655\u2013658","journal-title":"Ann Rheum Dis"},{"key":"3689_CR16","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/art.1780371206","volume":"37","author":"C Gabay","year":"1994","unstructured":"Gabay C, Gay-Croisier F, Roux-Lombard P, Meyer O, Maineti C, Guerne PA, Vischer T, Dayer JM (1994) Elevated serum levels of interleukin-1 receptor antagonist in polymyositis\/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 37:1744\u20131751","journal-title":"Arthritis Rheum"},{"key":"3689_CR17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.semarthrit.2011.10.005","volume":"41","author":"TA Kermani","year":"2012","unstructured":"Kermani TA, Schmidt J, Crowson CS, Ytterberg SR, Hunder GG, Matteson EL, Warrington KJ (2012) Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum 41:866\u2013871. doi: 10.1016\/j.semarthrit.2011.10.005","journal-title":"Semin Arthritis Rheum"},{"key":"3689_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/pgmj.74.867.1","volume":"74","author":"WY Tse","year":"1998","unstructured":"Tse WY, Cockwell P, Savage CO (1998) Assessment of disease activity in systemic vasculitis. Postgrad Med J 74:1\u20136","journal-title":"Postgrad Med J"},{"key":"3689_CR19","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00296-009-1291-y","volume":"30","author":"V Bagnari","year":"2010","unstructured":"Bagnari V, Colina M, Ciancio G, Govoni M, Trotta F (2010) Adult-onset Still\u2019s disease. Rheumatol Int 30:855\u2013862. doi: 10.1007\/s00296-009-1291-y","journal-title":"Rheumatol Int"},{"key":"3689_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00223-012-9684-4","volume":"92","author":"K Brabnikova Maresova","year":"2013","unstructured":"Brabnikova Maresova K, Pavelka K, Stepan JJ (2013) Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes. Calcif Tissue Int 92:354\u2013361. doi: 10.1007\/s00223-012-9684-4","journal-title":"Calcif Tissue Int"},{"key":"3689_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.bone.2013.08.016","volume":"57","author":"L Gifre","year":"2013","unstructured":"Gifre L, Ruiz-Gasp\u00e0 S, Monegal A, Nomdedeu B, Filella X, Gua\u00f1abens N, Peris P (2013) Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 57:272\u2013276. doi: 10.1016\/j.bone.2013.08.016","journal-title":"Bone"},{"key":"3689_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bbrc.2004.04.025","volume":"318","author":"K Ohnaka","year":"2004","unstructured":"Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R (2004) Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 318:259\u2013264. doi: 10.1016\/j.bbrc.2004.04.025","journal-title":"Biochem Biophys Res Commun"},{"key":"3689_CR23","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","volume":"19","author":"KE Poole","year":"2005","unstructured":"Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, L\u00f6wik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842\u20131844. doi: 10.1096\/fj.05-4221fje","journal-title":"FASEB J"},{"key":"3689_CR24","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.2106\/JBJS.M.01096","volume":"96","author":"JT Compton","year":"2014","unstructured":"Compton JT, Lee FY (2014) A review of osteocyte function and the emerging importance of sclerostin. J Bone Joint Surg Am 96:1659\u20131668. doi: 10.2106\/JBJS.M.01096","journal-title":"J Bone Joint Surg Am"},{"key":"3689_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00774-007-0821-5","volume":"26","author":"Y Kuroki","year":"2008","unstructured":"Kuroki Y, Kaji H, Kawano S, Kanda F, Takai Y, Kajikawa M, Sugimoto T (2008) Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study. J Bone Miner Metab 26:271\u2013278. doi: 10.1007\/s00774-007-0821-5","journal-title":"J Bone Miner Metab"},{"key":"3689_CR26","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.2169\/internalmedicine.55.6230","volume":"55","author":"K Shikano","year":"2016","unstructured":"Shikano K, Kaneko K, Kawazoe M, Kaburaki M, Hasunuma T, Kawai S (2016) Efficacy of vitamin K2 for glucocorticoid-induced osteoporosis in patients with systemic autoimmune diseases. Intern Med 55:1997\u20132003. doi: 10.2169\/internalmedicine.55.6230","journal-title":"Intern Med"},{"key":"3689_CR27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0009-8981(75)90167-9","volume":"63","author":"RJ Walton","year":"1975","unstructured":"Walton RJ, Preston CJ, Russell RG, Kanis JA (1975) An estimate of the turnover rate of bone-derived plasma alkaline phosphatase in Paget\u2019s disease. Clin Chim Acta 63:227\u2013229","journal-title":"Clin Chim Acta"},{"issue":"24","key":"3689_CR28","doi-asserted-by":"crossref","first-page":"12002","DOI":"10.1016\/S0021-9258(18)37885-2","volume":"263","author":"MJ Weiss","year":"1988","unstructured":"Weiss MJ, Ray K, Henthorn PS, Lamb B, Kadesch T, Harris H (1988) Structure of the human liver\/bone\/kidney alkaline phosphatase gene. J Biol Chem 263(24):12002\u201312010","journal-title":"J Biol Chem"},{"key":"3689_CR29","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1210\/mend.15.10.0704","volume":"15","author":"AM Delany","year":"2001","unstructured":"Delany AM, Durant D, Canalis E (2001) Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol 15:1781\u20131789. doi: 10.1210\/mend.15.10.0704","journal-title":"Mol Endocrinol"},{"key":"3689_CR30","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.bone.2004.05.023","volume":"35","author":"MK Sutherland","year":"2004","unstructured":"Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA (2004) Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35:828\u2013835. doi: 10.1016\/j.bone.2004.05.023","journal-title":"Bone"},{"key":"3689_CR31","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1210\/en.2007-0910","volume":"149","author":"FS Wang","year":"2008","unstructured":"Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL (2008) Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 149:1793\u20131801. doi: 10.1210\/en.2007-0910","journal-title":"Endocrinology"},{"key":"3689_CR32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1159\/000358303","volume":"60","author":"P Dovjak","year":"2014","unstructured":"Dovjak P, Dorfer S, F\u00f6ger-Samwald U, Kudlacek S, Marculescu R, Pietschmann P (2014) Serum levels of sclerostin and dickkopf-1: effects of age, gender and fracture status. Gerontology 60:493\u2013501. doi: 10.1159\/000358303","journal-title":"Gerontology"},{"key":"3689_CR33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3899\/jrheum.100089","volume":"38","author":"SY Wang","year":"2011","unstructured":"Wang SY, Liu YY, Ye H, Guo JP, Li R, Liu X, Li ZG (2011) Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol 38:821\u2013827. doi: 10.3899\/jrheum.100089","journal-title":"J Rheumatol"},{"key":"3689_CR34","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/jcb.20284","volume":"93","author":"GM Boland","year":"2004","unstructured":"Boland GM, Perkins G, Hall DJ, Tuan RS (2004) Wnt3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 93:1210\u20131230","journal-title":"J Cell Biochem"},{"key":"3689_CR35","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1359\/jbmr.070810","volume":"22","author":"CN Bennett","year":"2007","unstructured":"Bennett CN, Ouyang H, Ma YL, Zeng Q, Gerin I, Sousa KM, Lane TF, Krishnan V, Hankenson KD, MacDougald OA (2007) Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res 22:1924\u20131932","journal-title":"J Bone Miner Res"},{"key":"3689_CR36","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1002\/jbmr.118","volume":"25","author":"JR Stevens","year":"2010","unstructured":"Stevens JR, Miranda-Carboni GA, Singer MA, Brugger SM, Lyons KM, Lane TF (2010) Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells. J Bone Miner Res 25:2138\u20132147. doi: 10.1002\/jbmr.118","journal-title":"J Bone Miner Res"},{"key":"3689_CR37","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","volume":"87","author":"MC Hochberg","year":"2002","unstructured":"Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586\u20131592","journal-title":"J Clin Endocrinol Metab"},{"key":"3689_CR38","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00198-008-0816-7","volume":"20","author":"T Matsumoto","year":"2009","unstructured":"Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429\u20131437. doi: 10.1007\/s00198-008-0816-7","journal-title":"Osteoporos Int"},{"key":"3689_CR39","first-page":"354","volume":"28","author":"JN Hoes","year":"2010","unstructured":"Hoes JN, Jacobs JW, Hulsmans HM, De Nijs RN, Lems WF, Bruyn GA, Geusens PP, Bijlsma JW (2010) High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial. Clin Exp Rheumatol 28:354\u2013359","journal-title":"Clin Exp Rheumatol"},{"key":"3689_CR40","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00198-011-1675-1","volume":"23","author":"YE Chung","year":"2012","unstructured":"Chung YE, Lee SH, Lee SY, Kim SY, Kim HH, Mirza FS, Lee SK, Lorenzo JA, Kim GS, Koh JM (2012) Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int 23:1235\u20131243. doi: 10.1007\/s00198-011-1675-1","journal-title":"Osteoporos Int"},{"key":"3689_CR41","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bone.2011.11.028","volume":"50","author":"D Gatti","year":"2012","unstructured":"Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M (2012) Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50:739\u2013742. doi: 10.1016\/j.bone.2011.11.028","journal-title":"Bone"},{"key":"3689_CR42","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543. doi: 10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"key":"3689_CR43","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1002\/art.30385","volume":"63","author":"M Marenzana","year":"2011","unstructured":"Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, Robinson MK (2011) Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 63:2385\u20132395. doi: 10.1002\/art.30385","journal-title":"Arthritis Rheum"},{"key":"3689_CR44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00198-015-3308-6","volume":"27","author":"W Yao","year":"2016","unstructured":"Yao W, Dai W, Jiang L, Lay EY, Zhong Z, Ritchie RO, Li X, Ke H, Lane NE (2016) Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporos Int 27:283\u2013294. doi: 10.1007\/s00198-015-3308-6","journal-title":"Osteoporos Int"},{"key":"3689_CR45","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/jbmr.2869","volume":"31","author":"AY Sato","year":"2016","unstructured":"Sato AY, Cregor M, Delgado-Calle J, Condon KW, Allen MR, Peacock M, Plotkin LI, Bellido T (2016) Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost\/sclerostin. J Bone Miner Res 31:1791\u20131802. doi: 10.1002\/jbmr.2869","journal-title":"J Bone Miner Res"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3689-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3689-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3689-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T22:30:24Z","timestamp":1659047424000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3689-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,27]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["3689"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3689-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,27]]}}}